Neuralink Secures $650M Series E Funding as Brain Implant Trials Advance

Elon Musk’s Neuralink has raised $650 million in a Series E funding round, accelerating the development of its brain-computer interface technology. The round attracted heavyweight investors including ARK Invest, Sequoia Capital, and QIA, valuing the neurotechnology startup at approximately $9 billion.

Five patients with severe paralysis have already received Neuralink’s Telepathy implants, demonstrating successful control of external devices. The company currently runs clinical trials across three countries, with FDA Breakthrough Device designations for its Blindsight vision restoration and speech rehabilitation systems.

This capital injection follows a $280 million Series D in 2023, signaling growing confidence in Neuralink’s mission to address unmet medical needs through neurotechnology. The funds will expand patient access to what the company describes as ’independence-restoring’ neural interfaces.